Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I
Top Cited Papers
Open Access
- 1 September 2003
- Vol. 58 (9) , 752-756
- https://doi.org/10.1136/thorax.58.9.752
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is often associated with peripheral muscle weakness, which is caused by several factors. Acute exacerbations may contribute, but their impact on muscle force remains unclear. Correlations between peripheral muscle force and inflammatory and anabolic markers have never been studied in COPD. The effect of an acute exacerbation on quadriceps peak torque (QPT) was therefore studied in hospitalised patients, and the aforementioned correlations were examined in hospitalised and in stable patients. Methods: Lung function, respiratory and peripheral muscle force, and inflammatory and anabolic markers were assessed in hospitalised patients on days 3 and 8 of the hospital admission and 90 days later. The results on day 3 (n=34) were compared with those in clinically stable outpatients (n=13) and sedentary healthy elderly subjects (n=10). Results: Hospitalised patients had lowest mean (SD) QPT (66 (22)% predicted) and highest median (IQR) levels of systemic interleukin-8 (CXCL8, 6.1 (4.5 to 8.3) pg/ml). Insulin-like growth factor I (IGF-I) tended to be higher in healthy elderly subjects (p=0.09). QPT declined between days 3 and 8 in hospital (mean −5% predicted (95% CI −22 to 8)) and partially recovered 90 days after admission to hospital (mean 6% predicted (95% CI −1 to 23)). QPT was negatively correlated with CXCL8 and positively correlated with IGF-I and lung transfer factor in hospitalised and in stable patients. Conclusions: Peripheral muscle weakness is enhanced during an acute exacerbation of COPD. CXCL8 and IGF-I may be involved in the development of peripheral muscle weakness in hospitalised and in stable patients with COPD.Keywords
This publication has 44 references indexed in Scilit:
- Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failureJournal of the American College of Cardiology, 2002
- Myositis in Children with Meningococcal Disease: A Role for Tumour Necrosis Factor-α and Interleukin-8?Journal of Infection, 2002
- Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbationsThorax, 2001
- HIGH TUMOUR NECROSIS FACTOR-α LEVELS ARE ASSOCIATED WITH EXERCISE INTOLERANCE AND NEUROHORMONAL ACTIVATION IN CHRONIC HEART FAILURE PATIENTSCytokine, 2001
- Proteolysis‐inducing factor regulates hepatic gene expression via the transcription factors NF‐κΒ and STAT3The FASEB Journal, 2001
- Muscle weakness is related to utilization of health care resources in COPD patientsEuropean Respiratory Journal, 1997
- Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease.Thorax, 1996
- Characterization of a cancer cachectic factorNature, 1996
- Tumour necrosis factor‐α increases the ubiquitinization of rat skeletal muscle proteinsFEBS Letters, 1993
- Pharmacokinetics of Murine Tumor Necrosis FactorImmunopharmacology and Immunotoxicology, 1986